IDDI Complimentary Webinar on characteristics of Covid-19 trials and impact of the pandemic on clinical trials

The current SARS-CoV-2-induced coronavirus 2019 (COVID-19) pandemic has called for urgent design and implementation of clinical trials against this potentially life-threatening infection. The pandemic has also had a tremendous impact on ongoing clinical trials for all other indications. In both cases, the crisis has highlighted several limitations that currently exist and hinder a more agile and pragmatic, but at the same time ethically and scientifically sound, clinical-trials enterprise.

  • The key characteristics of COVID-19 trials, particularly with regard to trial-design features such as trial mechanics (including factorial and multi-stage designs, as well as platform trials), outcome assessment, and other important methodological issues.
  •  The impact the pandemic is having on clinical trials in several fields, including oncology and cardiology.
  • Practical issues pertaining to trial design and conduct, including for data capture, data management, statistical analysis, and patient follow-up, all of which affected by the current crisis.
Marc Buyse, ScD

Marc Buyse, ScD

Founder and Chief Scientific Officer

Everardo Saad, M.D.

Everardo Saad, M.D.

Medical Director

Back to Resources

View the Presentation

Trust Your Data to IDDI

Start Now